Angela Anne Guzzetta

Title: Angela Anne Guzzetta: Innovator in Epigenetic Drug Therapy

Introduction

Angela Anne Guzzetta is a prominent inventor based in Little Falls, NJ (US). She has made significant contributions to the field of epigenetics, particularly in predicting responses to epigenetic drug therapies. Her innovative work has the potential to transform treatment strategies for patients with varying immune signatures.

Latest Patents

Angela holds a patent titled "Predicting response to epigenetic drug therapy." This invention provides methods and compositions that are useful for predicting how patients will respond to epigenetic drug therapies. The invention identifies a unique signature known as the AZA Immune gene set or AIM, which differentiates patients with low and high immune signatures. This signature is regulated by epigenetic drugs, including demethylating drugs and histone deacetylase inhibitors. Patients with a high immune signature may benefit from immunotherapies such as anti-PD1 or anti-PDL1 antibodies or vaccines. Conversely, those with a low immune signature would benefit from treatment with epigenetic drugs followed by immunotherapy.

Career Highlights

Angela is affiliated with The Johns Hopkins University, where she continues her research and development in the field of epigenetics. Her work is recognized for its potential impact on personalized medicine and cancer treatment.

Collaborations

Angela has collaborated with notable colleagues, including Nita Ahuja and Stephen B. Baylin. Their combined expertise enhances the research and development of innovative therapeutic strategies.

Conclusion

Angela Anne Guzzetta is a trailblazer in the field of epigenetics, with her patent offering promising advancements in drug therapy. Her contributions are paving the way for more effective treatment options for patients, showcasing the importance of innovation in medical research.